Sign up
AIM

AIM ImmunoTech Inc (NYSE American: AIM)

Healthcare · Biotechnology

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. The borrow fee is 7.25%. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 36.3 (overbought above 70, oversold below 30)

Trend—

—

Short interest3.6% of float

FINRA settlement Oct 30, 2026

AIM price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range—
Volume—
Average volume (30 calendar days)—
Market cap—
P/E (TTM)—
Forward P/E—
EPS (TTM)—
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

AIM · NYSE American · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 17
Squeeze33Watch—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Insufficient coverage

0Strong Buy
1Buy
0Neutral
0Sell
0Strong Sell

Based on 1 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low—
Average—
High—

As of Nov 19, 2026 across 0 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

— · Earnings history not available

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellElectro Technik Industries, Inc.Sell$14.2KForm 4
Insider sellElectro Technik Industries, Inc.Sell$15.7KForm 4
Insider sellElectro Technik Industries, Inc.Sell$1.0KForm 4
Insider sellElectro Technik Industries, Inc.Sell$10.0KForm 4
Insider sellElectro Technik Industries, Inc.Sell$712Form 4
Insider sellElectro Technik Industries, Inc.Sell$9.9KForm 4
Insider sellElectro Technik Industries, Inc.Sell$6.5KForm 4
Insider sellElectro Technik Industries, Inc.Sell$2.7KForm 4
Insider sellElectro Technik Industries, Inc.Sell$2.0KForm 4
Insider sellElectro Technik Industries, Inc.Sell$11.6KForm 4
All smart-money activity →

News and press releases

All AIM news →

Company profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon

CEO
Mr. Thomas K. Equels Esq., J.D., M.S.
Headquarters
Ocala, FL, United States
Employees
19
IPO date
Jul 12, 1996
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.